ProQR Therapeutics N.V. (PRQR) is a Netherlands-based company that operates as a biopharmaceutical firm, focusing on the development and commercialization of treatments for rare, genetic diseases. The company takes a unique approach to tackling genetic disorders by correcting RNA mutations through a process called RNA repair. This process aims to correct the genetic fault causing the disease, with the hope of providing a one-time treatment.
Founded in 2012 by Daniel de Boer, a father inspired by his son's diagnosis of cystic fibrosis, ProQR Therapeutics has grown into a leading entity within the genetic therapeutics industry. As of now, it has several products in its pipeline addressing various disorders such as Leber’s congenital amaurosis 10 (LCA10), Usher syndrome, and dystrophic epidermolysis bullosa, among others.
The company's lead product candidate, sepofarsen (QR-110), is being developed for Leber's congenital amaurosis, a rare inherited retinal disease that affects infants and children, leading to vision loss. In Phase 1/2 and Phase 2/3 clinical trials, sepofarsen demonstrated substantial improvement in vision in treated patients, reflecting the potential of ProQR's RNA-targeting therapeutics.
Another key candidate in their pipeline is QR-421a for Usher syndrome and retinitis pigmentosa, diseases characterized by the progressive loss of both hearing and vision. This therapy is in the early stages of clinical development, permitting the testing of its safety and efficacy.
Expanding its focus, ProQR is developing Q-101, an RNA-based therapy targeting cystic fibrosis, the disease that initially inspired the company's foundation. This condition causes severe damage to the lungs and digestive system, affecting around 70,000 people globally.
ProQR Therapeutics N.V., listed on the NASDAQ (PRQR), continues to leverage cutting-edge RNA technology to create a transformative impact on patients' lives afflicted by severe genetic disorders. The passion and ambition behind the company have been recognized through partnerships with leading institutions and pharmaceutical companies. Determined to make a difference, ProQR carries its mission of breaking new grounds within genetic diseases by addressing the underlying cause with transformative RNA medicines.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
ProQR Therapeutics (NASDAQ:PRQR) has received an average "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $7.50, significantly higher than its current $1.90 opening price. The company surpassed quarterly earnings estimates, reporting a negative EPS of $0.09 against an expected negative $0.13, and revenue of $10 million against an anticipated $4.56 million. Insider transactions show executives and directors purchased 600,000 shares worth $988,500 in the last 90 days.
ProQR Therapeutics has commenced its AX-0811 early-phase clinical trial by administering the RNA editing treatment candidate to the first participant. This study, focusing on NTCP modulation for cholestatic liver diseases like biliary atresia, will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers. Preliminary target-engagement results are expected in early January 2027.
ProQR Therapeutics (NASDAQ:PRQR) shares have surpassed their 50-day moving average, reaching $2.11 and closing at $2.05, exceeding the average of $1.92. The company reported better-than-expected quarterly results, with a smaller adjusted loss per share and higher revenue than projected. Analysts maintain a "Moderate Buy" rating with an average price target of $7.50, and insiders have recently purchased a significant number of shares.
ProQR Therapeutics (NASDAQ:PRQR) saw its share price cross above its 50-day moving average, trading at $2.32 compared to the average of $1.87. This comes amidst positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.50, and better-than-expected quarterly results. Additionally, company insiders have recently purchased 600,000 shares, signaling confidence in the stock.
Bank of America Securities initiated coverage on ProQR Therapeutics NV (PRQR) with a buy rating and an $8 price target, validating its Axiomer RNA-editing platform. Despite its early development stage, unprofitability, and negative cash flow, the stock is considered moderately undervalued by GuruFocus's GF Value™ at $2.45, with strong insider buying indicating management confidence. The company’s GF Score™ of 50/100 highlights strengths in valuation and momentum, balanced by concerns in financial strength.